NDAORALTABLET
Approved
Apr 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
3
Data completeness
5/8 — Partial
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CUVRIOR (trientine tetrahydrochloride) is an oral small-molecule chelating agent approved in April 2022 for copper metabolism disorders, most notably Wilson disease. It works by binding and removing excess copper from the body through urinary excretion.
$0.378MPart D
Peak13.0 years to LOEEarly-stage peak lifecycle with minimal Medicare uptake signals small commercial team focused on rare disease market penetration and specialist engagement.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.
Started Jul 2026
38 enrolled
Wilson's Disease
Patient Preference Study: Standard of Care Versus Once-daily Trientine Tetrahydrochloride
Started Jul 2025
10 enrolled
Wilson's Disease
Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease
Started Sep 2018
77 enrolled
Wilson Disease
Career Relevance
CUVRIOR employment opportunities are highly concentrated in communications/patient education roles, reflecting Orphalan's focus on rare disease awareness and specialist outreach. Career growth is limited by the small commercial footprint and niche market, making this a specialized rather than high-volume career opportunity.
Worked on CUVRIOR at Orphalan? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.